子宮平滑肌惡性肉瘤案例報告

Uterine Leiomyosarcoma: A Case Report

10.53106/168232812021123104006

蕭文棋(Wen-Chi Hsiao)；劉世明(Shih-Ming Liu)；陳民虹(Ming-Hung Chen)

非典型子宮肌瘤 ； 子宮平滑肌惡性肉瘤 ； atypical leiomyoma ； uterine leiomyosarcoma

台灣家庭醫學雜誌

31卷4期（2021 / 12 / 01）

304 - 313

繁體中文

本文報告一位41歲女性，因持續兩週的下腹悶痛及腫塊求診，術後確診為子宮平滑肌惡性肉瘤，她在兩年半前曾接受腹腔鏡子宮肌瘤切除術，診斷為非典型子宮肌瘤。子宮平滑肌惡性肉瘤的發生率極低，目前超音波及電腦斷層尚無法和子宮肌瘤明確區分，而核磁共振是一個相當敏感的工具，因此若腫瘤超過8 cm或生長快速，宜進一步以核磁共振或以組織切片或直接手術探查。此外，非典型子宮肌瘤，雖多數為良性，但有進展為惡性肉瘤的可能，建議在術後至少5年內，每半年接受骨盆腔理學檢查，每年胸部X光攝影及骨盆腔影像學檢查，以早期發現復發或惡性的腫瘤。

We herein reported a 41-year-old woman presenting with two weeks of lower abdominal mass and dull pain. She underwent total hysterectomy with bilateral salpingo-oophorectomy, and the pathology examination revealed uterine leiomyosarcoma. The patient had a surgical history of laparoscopic myomectomy with a pathologic diagnosis of atypical leiomyoma of the uterus two and a half years ago. The incidence of uterine leiomyosarcoma is very low. In the modern era, echography and computed tomography remain unable to clearly differentiate uterine leiomyosarcoma from leiomyoma, whereas MRI is a sensitive tool for diagnosis. Therefore, if a lower abdominal mass is more than 8 cm or rapidly growing, MRI, biopsy, or laparoscopic exploration, is strongly recommended. Moreover, while atypical leiomyoma of the uterus is mostly benign in nature, it has a high rate of recurrence and the potential of transformation into leiomyosarcoma. Hence, for early detection of recurrence, pelvic examination twice a year, annual chest X-ray, and pelvic imaging are recommended for at least 5 years postoperatively in these cases.

1. American Cancer Society: Survival Rates for Uterine Sarcoma. https://www.cancer.org/cancer/uterine-sarcoma/detection-diagnosis-staging/survival-rates.html Accessed December 6, 2020.
2. Arleo, EK,Schwartz, PE,Hui, P,McCarthy, S(2015).Review of leiomyoma variants.AJR Am J Roentgenol,205,912-921.
3. Bužinskien, D,Miknas, S,Dr, sutien, G,Mongirdas, M(2018).Uterine sarcoma: a clinical case and a literature review.Acta Med Litu,25,206-218.
4. Cho, HY,Kim, K,Kim, YB,No, JH(2016).Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics.J Obstet Gynaecol Res,42,313-318.
5. Cui, RR,Wright, JD,Hou, JY(2017).Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.BJOG,124,1028-1037.
6. Ip, PP,Cheung, AN(2011).Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.Best Pract Res Clin Obstet Gynaecol,25,691-704.
7. Juhasz-Böss, I,Gabriel, L,Bohle, RM(2018).Uterine leiomyosarcoma.Oncol Res Treat,41,680-686.
8. Kawamura, N,Ichimura, T,Ito, F(2002).Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma.Cancer,94,1713-1720.
9. Kim, HS,Han, KH,Chung, HH(2010).Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison.Eur J Surg Oncol,36,691-698.
10. Koivisto-Korander, R,Martinsen, JI,Weiderpass, E,Pukkala, E(2012).Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases.Maturitas,72,56-60.
11. Kusunoki, S,Terao, Y,Ujihira, T(2017).Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI.Taiwan J Obstet Gynecol,56,508-513.
12. Manxhuka-Kerliu, S,Kerliu-Saliu, I,Sahatciu-Meka, V,Kerliu, L,Shahini, L(2016).Atypical uterine leiomyoma: a case report and review of the literature.J Med Case Rep,10,22.
13. Mbatani, N,Olawaiye, AB,Prat, J(2018).Uterine sarcomas.Int J Gynaecol Obstet,143(Suppl 2),51-58.
14. Nagai, T,Takai, Y,Akahori, T(2014).Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass.Springerplus,3,678.
15. Nishigaya, Y,Kobayashi, Y,Matsuzawa, Y(2019).Diagnostic value of combination serum assay of lactate dehydrogenase, D-dimer, and C-reactive protein for uterine leiomyosarcoma.J Obstet Gynaecol Res,45,189-194.
16. Pados, G,Tsolakidis, D,Theodoulidis, V(2017).Prevalence of occult leiomyosarcomas and atypical leiomyomas after laparoscopic morcellation of leiomyomas in reproductive- age women.Hum Reprod,32,2036-2041.
17. Rio, G,Lima, M,Gil, R,Horta, M,Cunha, TM(2019).T2 hyperintense myometrial tumors: can MRI features differentiate leiomyomas from leiomyosarcomas?.Abdom Radiol,44,3388-3397.
18. Schwartz, PE,Kelly, MG(2006).Malignant transformation of myomas: myth or reality?.Obstet Gynecol Clin North Am,33,183-198.
19. Tong, A,Kang, SK,Huang, C,Huang, K,Slevin, A,Hindman, N(2019).MRI screening for uterine leiomyosarcoma.J Magn Reson Imaging,49,e282-e294.
20. Tulandi, T,Leung, A,Jan, N(2016).Nonmalignant sequelae of unconfined morcellation at laparoscopic hysterectomy or myomectomy.J Minim Invasive Gynecol,23,331-337.
21. Wen, KC,Horng, HC,Wang, PH(2016).Uterine sarcoma part I-uterine leiomyosarcoma: the topic advisory group systematic review.Taiwan J Obstet Gynecol,55,463-471.
22. Zhang, Q,Ubago, J,Li, L(2014).Molecular analyses of 6 different types of uterine smooth muscle tumors: emphasis in atypical leiomyoma.Cancer,120,3165-3177.
23. 衛生福利部國民健康署：癌症登記報告。2020年12月1日，取自https://www.hpa.gov. tw/Pages/List.aspx?nodeid=269.